Vimarsana
Biggest News Aggregation in the World

Progression Marker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Progression Marker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Progression Marker Today - Breaking & Trending Today

Michael J. Fox Net Worth: How Rich Is He? Wife, Philanthropy, And More - Vimarsana News

Michael J. Fox Net Worth: How Rich Is He? Wife, Philanthropy, And More

Michael J. Fox Net Worth: Discover the net worth of Canadian-American activist and retired Actor, his wife, philanthropy work, and more.

Source: sdgln.com
'Big step forward': New lab tests may accelerate Parkinson's diagnosis and research - Vimarsana News

'Big step forward': New lab tests may accelerate Parkinson's diagnosis and research

A lab test that can tell doctors if someone has Parkinson’s disease is a long-sought goal of researchers.

'Big step forward': New lab tests may accelerate Parkinson's diagnosis and research - Vimarsana News

'Big step forward': New lab tests may accelerate Parkinson's diagnosis and research

A lab test that can tell doctors if someone has Parkinson's disease is a long-sought goal of researchers.

Source: wxow.com
New lab tests may accelerate Parkinson's diagnosis and research - Vimarsana News

New lab tests may accelerate Parkinson's diagnosis and research

A lab test that can tell doctors if someone has Parkinson's disease is a long-sought goal of researchers.

Source: abc12.com
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia - Vimarsana News

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia

Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to... | March 30, 2023